Studies of alternative horse ATG/CsA regimens compared with standard horse ATG/CsA
| Study (year) . | N . | Agent(s) added to horse ATG/CsA . | Design . | Outcome compared with standard horse ATG/CsA . |
|---|---|---|---|---|
| Kojima (2000)65 | 119 | G-CSF, danazol | Prospective, randomized | No difference in response, relapse, clonal evolution, or survival |
| Gluckman (2002)89 | 102 | G-CSF | Prospective, randomized | No difference in response, relapse, clonal evolution, or survival |
| Zheng (2006)77 | 77 | GM-CSF, EPO | Prospective, randomized | No difference in response or survival |
| Scheinberg (2006)67 | 104 | Mycophenolate mofetil | Prospective | No difference in response, relapse, clonal evolution, or survival compared with historical control |
| Teramura (2007)92 | 101 | G-CSF | Prospective, randomized | No difference in response, clonal evolution, and survival; fewer relapses in G-CSF arm |
| Scheinberg (2009)68 | 77 | Sirolimus | Prospective, randomized | No difference in response, relapse, clonal evolution, or survival |
| Tichelli (2011)94 | 192 | G-CSF | Prospective, randomized | No difference in response, relapse, event-free survival, and overall survival |
| Study (year) . | N . | Agent(s) added to horse ATG/CsA . | Design . | Outcome compared with standard horse ATG/CsA . |
|---|---|---|---|---|
| Kojima (2000)65 | 119 | G-CSF, danazol | Prospective, randomized | No difference in response, relapse, clonal evolution, or survival |
| Gluckman (2002)89 | 102 | G-CSF | Prospective, randomized | No difference in response, relapse, clonal evolution, or survival |
| Zheng (2006)77 | 77 | GM-CSF, EPO | Prospective, randomized | No difference in response or survival |
| Scheinberg (2006)67 | 104 | Mycophenolate mofetil | Prospective | No difference in response, relapse, clonal evolution, or survival compared with historical control |
| Teramura (2007)92 | 101 | G-CSF | Prospective, randomized | No difference in response, clonal evolution, and survival; fewer relapses in G-CSF arm |
| Scheinberg (2009)68 | 77 | Sirolimus | Prospective, randomized | No difference in response, relapse, clonal evolution, or survival |
| Tichelli (2011)94 | 192 | G-CSF | Prospective, randomized | No difference in response, relapse, event-free survival, and overall survival |
Only comparative studies that included cyclosporine with ATG are included.
EPO indicates erythropoietin.